HEPA · Hepion Pharmaceuticals, Inc. · Financials
$0.14
-0.18 (-57.55%)
At close · May 13
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”View the 10-Q filed Aug 13, 2026
Market Cap
$6.77M
Shares
90.22M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2023
Net Income
-$8.28M
+37.3%
FY2025
Diluted EPS
-$0.88
+99.2%
FY2025
Operating Cash Flow
-$3.27M
+82%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | |
| $120.92K | $445.51K | $11.85M | $35.64M | $33.27M | $20.4M | $12M | $3.18M | $7.59M | $13.37M | $15.02M | $8.4M | $314.25K | |
| $3.03M | $3.32M | $7.5M | $9.62M | $10.35M | $10.01M | $8.15M | $4.59M | $7M | $7.28M | $5.79M | $5.56M | $1.36M | |
| — | — | $30.76K | $67.13K | $77.46K | $86.07K | $34.52K | $26.74K | $18.79K | $27.99K | $21.53K | $16.36K | $1321 | |
| $3.15M | $4.16M | $19.35M | $48.45M | $45.49M | $30.4M | $20.15M | $7.77M | $14.59M | $21.02M | $20.81M | — | — | |
| -$3.15M | -$4.16M | -$19.35M | -$48.45M | -$45.49M | -$30.4M | -$20.15M | -$7.77M | -$14.59M | -$20.65M | -$20.81M | -$13.96M | -$1.67M | |
| — | — | -$19.32M | -$48.38M | -$45.41M | -$30.32M | -$20.11M | -$7.74M | -$14.58M | — | -$20.78M | -$13.94M | -$1.67M | |
| $11.49K | — | — | $9465 | $10.16K | $8859 | $31.23K | $555K | $339.16K | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $4.22M | $3.81M | -$387.9K | -$3.61M | |
| — | -$8.28M | -$16.16M | -$49.34M | -$45.08M | -$32.72M | -$20.32M | -$7.95M | -$9.99M | -$15.03M | -$17M | — | — | |
| — | — | -$2.97M | -$409.02K | -$2.88M | $0 | $30.58K | -$908.68K | -$536K | -$1.95M | — | $0 | $0 | |
| -$3.19M | -$8.28M | -$13.19M | -$48.93M | -$42.2M | -$32.72M | -$20.35M | -$7.04M | -$9.45M | -$14.89M | -$17M | -$14.35M | — | |
| — | — | — | -$48.93M | -$45.34M | -$32.72M | -$20.36M | -$12.48M | -$17.9M | -$13.08M | -$17M | -$22.19M | -$5.28M | |
| -$3.19M | -$8.28M | -$13.11M | -$48.91M | -$42.29M | -$32.72M | — | — | — | — | -$17M | — | — | |
| USD/shares | $1.21 | -$0.88 | -$107.35 | -$616.07 | -$595.00 | -$470.00 | -$2,100.00 | -$5,950.00 | -$97,350.00 | -$260.00 | — | — | — |
| USD/shares | $1.21 | -$0.88 | -$107.35 | -$616.07 | -$595.00 | -$470.00 | -$2,100.00 | — | -$1,390.00 | -$300.00 | — | — | — |
| shares | — | 9.41M | 122.89K | 79.42K | 76.23K | 70.29K | 9677.832 | 2043.244 | 183.879 | 9678.329 | 27.06K | 21.75K | 12.82K |
| shares | — | 9.41M | 122.89K | 79.42K | 76.23K | 70.29K | 9677.832 | 2043.244 | 12.87K | 9678.329 | 27.06K | 21.75K | 12.82K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.84×
EV/EBIT
—
P/E (TTM)
—
Peer median 1.90×
Peer medians compare against the 181 similar-size Biotechnology companies (of 534 listed).